A four-week nutrition education program focused on how food interacts with Parkinson’s disease medications was tied to improved physical and mental quality of life for patients, a small study in Turkey found. The program helped participants adjust their eating habits, providing guidance on timing protein-rich meals around doses of…
News
Phase 1 trial results showed an experimental oral therapy was associated with improved eye movement control, lower levels of neuroinflammatory biomarkers, and higher markers of nerve cell health in people with Parkinson’s disease. The results from the ARV-102-103 trial (EUCT 2024-516888-84-00) build on findings presented earlier this year…
The 150 mg dose of solengepras (CVN424), Cerevance’s investigational oral treatment for Parkinson’s disease, significantly reduced average daily off time — periods when symptoms reappear despite medication — compared with placebo, according to topline results from a Phase 3 trial. The Phase 3 ARISE trial (NCT06553027) evaluated…
A real-world study found that psychiatric issues, including hallucinations and delusions, developed in some people with advanced Parkinson’s disease after they started Vyalev (foscarbidopa and foslevodopa), but most were manageable with infusion-rate adjustments or low-dose antipsychotic medications. The study, “…
The first patient has been dosed in a Phase 2a clinical trial evaluating Jotrol, an investigational oral formulation of resveratrol that Jupiter Neurosciences is developing for Parkinson’s disease. The trial is expected to be completed in the first half of 2029. The RESET trial (NCT07592767) is enrolling…
Amprion and Prema Cognition have entered into a collaboration to explore an approach for identifying and evaluating people at risk for Parkinson’s disease and related disorders that combines digital cognitive testing with molecular biomarker analysis. The partnership will pair Premas’ cognitive assessment technology, called Premaz, with…
Chemical changes in the brain region known as the cerebellum may play a key role in the cognitive issues experienced by people with Parkinson’s disease, a study found. The researchers used specialized MRI scans to track glutamate, a brain signaling molecule, and pinpoint…
The first Parkinson’s disease patient has been implanted with Newronika‘s adaptive AlphaDBS, an innovative deep brain stimulation (DBS) system, as part of a pivotal clinical trial underway in Italy. The ADVENT study (NCT06891781) will compare the adaptive AlphaDBS system with conventional DBS in people with Parkinson’s. The trial…
Blue light therapy delivered through Chrono Eyewear’s Propeaq glasses may help people with Parkinson’s disease sleep better and feel less sleepy during the day, a small study shows. After two weeks, those using blue light glasses reported greater improvements in sleep quality and daytime alertness, as well as…
Gain Therapeutics’ oral therapy candidate rexaceract, formerly called GT-02287, stabilized motor symptoms in a small group of people with Parkinson’s disease who were treated for one year. That’s according to new data from an open-label extension of an early clinical trial, which showed no meaningful progression of Parkinson’s…
Recent Posts
- Short nutrition course may improve life for Parkinson’s patients
- My uncle’s red recliner had a front-row seat to his life with Parkinson’s
- Parkinson’s drug shifts key biomarkers, trial results show
- My dad’s weightlifting regimen helped him fight back against Parkinson’s
- Once-daily treatment may reduce Parkinson’s off time, study finds